Investigational Drugs and Stem Cell Treatments: Legal and Ethical Considerations of Right to Try Laws


Wednesday, December 2, 2020, 12:30pm


Virtual, via Zoom - register to receive the link via email

Ethics banner image

Access to investigational drugs has been a controversial topic during the COVID19 pandemic: what is the level of evidence required? How do we evaluate individual access requests, particularly from public figures such as outgoing Presidents? How does providing access change the ability to acquire fundamental information about these products? In May 2018, the Right to Try Act was signed into law, creating a new pathway for patients with life-threatening conditions to access investigational products prior to FDA approval. Prior to the federal law, more than half of states had passed their own versions of right to try. Two expert panelists will consider the scientific, legal, and ethical issues relating to access to investigational treatments and how Right to Try laws change the landscape for the future.

George Q. Daley, MD, PhD

Dean of the Faculty of Medicine
Harvard Medical School

Alison Bateman-House, MPH, PhD
Assistant Professor
Department of Population Health
NYU Grossman School of Medicine

Insoo Hyun, PhD

Director of Research Ethics
Center for Bioethics
Harvard Medical School
Professor of Bioethics
Case Western Reserve University
School of Medicine